The following is a summary of the Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Vaxart reported Q1 2024 revenue of $2.2 million, primarily from revenue recognized under BARDA contract and non-cash royalty revenue from Inavir sales in Japan.

• The company ended the first quarter with cash, cash equivalents, and investments amounting to $36.7 million.

Business Progress:

• Positive results from Phase 1 clinical trial evaluating Vaxart's oral pill bivalent norovirus vaccine candidate in lactating mothers.

• Vaxart plans to discuss the progress of their norovirus program with the FDA in mid-2024.

• Vaxart is preparing to initiate a Phase 2b trial for their COVID-19 vaccine candidate XBB as early as Q2 2024, pending additional funds and regulatory alignment.

• The company is set to accelerate investment in their vaccine pipeline owing to promising preclinical data from their COVID-19 XBB construct.

• A meeting with the FDA to review clinical findings and inform future regulatory pathway and clinical steps is planned for mid-2024.

• Vaxart has enough vaccine material produced for the upcoming Phase 2b COVID study.

• Vaxart considers their oral pill vaccine technology to be a potential tool against vaccine hesitancy.

• The company continues promoting its vaccine benefits to the medical community.

More details: Vaxart IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.